# Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

> **NCT00205478** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 300 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** VX-702

## Key facts

- **NCT ID:** NCT00205478
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 300 (—)
- **Last updated:** 2007-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00205478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00205478, "Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00205478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*